You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Nanopore sequencing as a scalable, cost-effective platform for analyzing polyclonal vector integration sites following clinical T cell therapy

Article info

Article menu

Download PDFPDF

XML
Immune cell therapies and immune cell engineering
Original research
Nanopore sequencing as a scalable, cost-effective platform for analyzing polyclonal vector integration sites following clinical T cell therapy

Authors

  • Ping Zhang Department of Immunology, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia PubMed articlesGoogle scholar articles
  • Devika Ganesamoorthy Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia PubMed articlesGoogle scholar articles
  • Son Hoang Nguyen Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia PubMed articlesGoogle scholar articles
  • Raymond Au Department of Immunology, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia PubMed articlesGoogle scholar articles
  • Lachlan J Coin Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia Department of Clinical Pathology, The University of Melbourne, Melbourne, Victoria, Australia Department of Infectious Disease, Imperial College London, London, London, UK PubMed articlesGoogle scholar articles
  • Siok-Keen Tey Department of Immunology, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia Department of Haematology and Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Siok-Keen Tey; siok.tey{at}qimrberghofer.edu.au
View Full Text

Citation

Zhang P, Ganesamoorthy D, Nguyen SH, et al
Nanopore sequencing as a scalable, cost-effective platform for analyzing polyclonal vector integration sites following clinical T cell therapy
Journal for ImmunoTherapy of Cancer 2020;8:e000299. doi: 10.1136/jitc-2019-000299

Publication history

  • Accepted March 28, 2020
  • First published June 10, 2020.
Online issue publication 
January 11, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.